Leap Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Leap Therapeutics generated cash of -$43,753,000, which is more than the previous year. Cash used in financing activities reached the amount of -$30,000 last year. Net change in cash is therefore $5,143,000.
Cash Flow
| 2014 | -18.01M | -36.80M | 46.88M |
|---|---|---|---|
| 2015 | -19.58M | 29.69M | 16K |
| 2016 | -25.33M | -144K | 25.61M |
| 2017 | -22.13M | -64K | 47.76M |
| 2018 | -26.03M | 0 | 15.90M |
| 2019 | -26.90M | -85K | 14.81M |
| 2020 | -25.95M | 25K | 73.99M |
| 2021 | -35.15M | 0 | 98.03M |
| 2022 | -49.04M | 0 | -210K |
| 2023 | -43.75M | 48.96M | -30K |
LPTX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 65.5M | 114.91M | 52.07M | 3.89M | 16.28M | 25.73M | 793K | 405K | 10.86M | 18.99M |
Operating activities | ||||||||||
Net income | -81.41M | -54.59M | -40.58M | -27.51M | -32.9M | -23.13M | -29.72M | -25.63M | -21.10M | -25.45M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 15K | 16K | 29K | 34K | 47K | 49K | 48K | 25K | 474K | 657K |
Stock-based compensation expense | 5.12M | 5.18M | 3.48M | 2.61M | 3.89M | 0 | 5.6M | 45K | 1.72M | 1.66M |
| Deferred income tax benefit | 5.12M | 5.18M | 3.48M | 2.61M | 3.89M | 0 | 5.6M | 45K | 1.72M | 1.66M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 1.30M | -1.00M | -1.15M | 117K | 643K | 780K | 1.45M | -3.05M | 0 | 0 |
Inventories | 0 | 1.00M | 1.15M | -117K | -643K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 712K | 945K | 3.9M | -2.60M | 1.08M | 368K | 1.09M | 2.26M | 0 | 0 |
Cash generated by operating activities | -43.75M | -49.04M | -35.15M | -25.95M | -26.90M | -26.03M | -22.13M | -25.33M | -19.58M | -18.01M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -418K | -35.39M |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | -100K | 0 | -64K | -144K | -12K | -227K |
Acquisitions Net | 50.36M | 0 | 0 | 25K | 15K | 0 | 0 | 0 | 61K | 0 |
Cash generated by investing activities | 48.96M | 0 | 0 | 25K | -85K | 0 | -64K | -144K | 29.69M | -36.80M |
Financing activities | ||||||||||
Common Stock Issued | 0 | -210K | 97.22M | 48.51M | 15.25M | 15.03M | 49.16M | -282K | 3.87M | 46.68M |
Payments for dividends | 0 | 0 | 0 | 0 | -359K | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 750K | -25.9M | 4.4M | 0 |
Cash used in financing activities | -30K | -210K | 98.03M | 73.99M | 14.81M | 15.90M | 47.76M | 25.61M | 16K | 46.88M |
Net Change In Cash | 5.14M | -49.41M | 62.84M | 48.18M | -12.39M | -9.45M | 24.94M | 388K | 10.09M | -8.12M |
Cash at end of period | 70.64M | 65.5M | 114.91M | 52.07M | 3.89M | 16.28M | 25.73M | 793K | 20.96M | 10.86M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |